

Glyn B Steventon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7833698/publications.pdf>

Version: 2024-02-01

39
papers

1,095
citations

687363

13
h-index

395702

33
g-index

40
all docs

40
docs citations

40
times ranked

1515
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma cysteine and sulphate levels in patients with motor neurone, Parkinson's and Alzheimer's disease. <i>Neuroscience Letters</i> , 1990, 110, 216-220.	2.1	412
2	The sulphorhodamine (SRB) assay and other approaches to testing plant extracts and derived compounds for activities related to reputed anticancer activity. <i>Methods</i> , 2007, 42, 377-387.	3.8	250
3	Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache. <i>Journal of the Neurological Sciences</i> , 1998, 156, 102-106.	0.6	86
4	Use of Human Microsomes and Deuterated Substrates: An Alternative Approach for the Identification of Novel Metabolites of Ketamine by Mass Spectrometry. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1769-1778.	3.3	54
5	In-vitro effect of flavonoids from <i>Solidago canadensis</i> extract on glutathione S-transferase. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 58, 251-256.	2.4	23
6	Uridine diphosphate glucuronosyltransferase 1A1. <i>Xenobiotica</i> , 2020, 50, 64-76.	1.1	21
7	Characterization and purification of the vitamin K1 2,3 epoxide reductase system from rat liver. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 53, 481-486.	2.4	20
8	Phenylalanine hydroxylase: possible involvement in the S-oxidation of S-carboxymethyl-L-cysteine. <i>Analytical Biochemistry</i> , 2004, 335, 91-97.	2.4	18
9	The activity of wild type and mutant phenylalanine hydroxylase with respect to the C-oxidation of phenylalanine and the S-oxidation of S-carboxymethyl-L-cysteine. <i>Molecular Genetics and Metabolism</i> , 2009, 96, 27-31.	1.1	17
10	S-Carboxymethyl-L-cysteine. <i>Drug Metabolism Reviews</i> , 2012, 44, 129-147.	3.6	17
11	Phenylalanine 4-Monooxygenase and the S-Oxidation of S-Carboxymethyl-L-cysteine. <i>Drug Metabolism and Drug Interactions</i> , 2004, 20, 159-174.	0.3	16
12	Monoamine oxidase substrates in Parkinson's disease. <i>Biochemical Pharmacology</i> , 1990, 40, 2562-2564.	4.4	15
13	PHENYLALANINE 4-MONOOXYGENASE AND THE S-OXIDATION OF S-CARBOXYMETHYL-L-CYSTEINE IN HepG2 CELLS. <i>Drug Metabolism and Drug Interactions</i> , 2005, 21, 1-18.	0.3	15
14	Human phenylalanine monooxygenase and thioether metabolism. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 63-67.	2.4	14
15	Catalytic properties of CYP1A isoforms in the liver of an agnathan (<i>Lampetra fluviatilis</i>) and two species of teleost (<i>Pleuronectes flesus</i> , <i>Anguilla anguilla</i>). <i>Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology</i> , 2000, 125, 203-214.	0.5	12
16	CYP1A2 IN A SMOKING AND A NON-SMOKING POPULATION: CORRELATION OF URINARY AND SALIVARY PHENOTYPIC RATIOS. <i>Drug Metabolism and Drug Interactions</i> , 2004, 20, 247-61.	0.3	10
17	Phenylalanine 4-monooxygenase and the S-Oxidation of S-Carboxymethyl-L-cysteine by Human Cytosolic Fractions. <i>Drug Metabolism and Drug Interactions</i> , 2008, 23, 261-82.	0.3	10
18	Mouse recombinant phenylalanine monooxygenase and the S-oxidation of thioether substrates. <i>Journal of Biochemical and Molecular Toxicology</i> , 2009, 23, 119-124.	3.0	9

#	ARTICLE	IF	CITATIONS
19	Phenylalanine 4-monooxygenase and the role of endobiotic metabolism enzymes in xenobiotic biotransformation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 1213-1221.	3.3	7
20	Lack of congruence between cysteine dioxygenase activity and S-carboxymethyl-L-cysteine S-oxidation activity in rat cytosol. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 993-1000.	2.4	6
21	An Investigation into the Inter-Relationships of Sulphur Xeno- Biotransformation Pathways in Parkinson's and Motor Neurone Diseases. <i>Drug Metabolism and Drug Interactions</i> , 2003, 19, 223-240.	0.3	5
22	The pharmacokinetics of orally administered S-carboxymethyl-L-cysteine in the dog, calf and sheep. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 39, 219-223.	4.0	5
23	Recombinant heteromeric phenylalanine monooxygenase and the oxygenation of carbon and sulfur substrates. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 558-564.	2.4	5
24	An investigation into possible xenobioticâ€œendobiotic inter-relationships involving the amino acid analogue drug, S-carboxymethyl-L-cysteine and plasma amino acids in humans. <i>Amino Acids</i> , 2012, 42, 1967-1973.	2.7	5
25	Phenylalanine monooxygenase and the sulfur oxygenation of S-carboxymethyl-L-cysteine in mice. <i>Xenobiotica</i> , 2016, 46, 379-384.	1.1	5
26	Comparison of the sulfur-oxygenation of cysteine and S-carboxymethyl-L-cysteine in human hepatic cytosol and the role of cysteine dioxygenase. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 70, 1069-1077.	2.4	5
27	Phenylalanine 4-monooxygenase: the â€œsulfoxidation polymorphismâ€œ. <i>Xenobiotica</i> , 2020, 50, 51-63.	1.1	5
28	CARBOCYSTEINE THERAPY IN OLDER PEOPLE WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1792-1793.	2.6	4
29	Phenylalanine hydroxylase: A biomarker of disease susceptibility in Parkinsonâ€™s disease and Amyotrophic lateral sclerosis. <i>Medical Hypotheses</i> , 2018, 118, 29-33.	1.5	4
30	PREFACE for the special issue of xenobiotica on â€œpharmacogenetics of drug metabolismâ€œ. <i>Xenobiotica</i> , 2020, 50, 1-2.	1.1	3
31	S-carboxymethyl-L-cysteine and its (R/S)-S-oxides in beagle dog plasma and hepatic cytosol. <i>Xenobiotica</i> , 2015, 45, 1047-1053.	1.1	2
32	Drug S-oxidation and phenylalanine hydroxylase: a biomarker for neurodegenerative susceptibility in Parkinsonâ€™s disease and amyotrophic lateral sclerosis. <i>Drug Metabolism and Personalized Therapy</i> , 2019, 34, .	0.6	2
33	The S-oxidation of S-carboxymethyl-L-cysteine in hepatic cytosolic fractions from BTBR and phenylketonuria enu1 and enu2 mice. <i>Xenobiotica</i> , 2019, 49, 495-502.	1.1	2
34	Metabolic Fate of Phenothiazine in the Marmoset (<i>Callithrix jacchus</i>). <i>Drug Metabolism and Drug Interactions</i> , 2009, 24, 137-152.	0.3	1
35	Measurement of Phenylalanine Monooxygenase (PAH) Activities. <i>Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et al]</i> , 2009, 41, Unit4.29.	1.1	1
36	S-Carboxymethyl-L-cysteine: a multiple dosing study using pharmacokinetic modelling. <i>Xenobiotica</i> , 2021, 51, 865-870.	1.1	1

#	ARTICLE	IF	CITATIONS
37	Drug peptide conjugates in human urine?. <i>Xenobiotica</i> , 2014, 44, 89-93.	1.1	0
38	Xenobiotic Conjugation with Dicarboxylic Acids. <i>Current Drug Metabolism</i> , 2018, 19, 1130-1137.	1.2	0
39	Phenylalanine monooxygenase and the "sulfoxidation polymorphism"; the salient points. <i>Drug Metabolism and Personalized Therapy</i> , 2022, .	0.6	0